Maxim Group analyst Jason McCarthy downgrades Kintara Therapeutics (NASDAQ:KTRA) from Buy to Hold.
Maxim Group Downgrades Kintara Therapeutics to Hold
Maxim Group analyst Jason McCarthy downgrades Kintara Therapeutics (NASDAQ:KTRA) from Buy to Hold.
Related Posts
Why Okta Stock Is Hitting New 52-Week Lows Today
Okta Inc (NASDAQ: OKTA) shares are trading lower Thursday after the company reported second-quarter results and issued guidance below analyst estimates.
Information Technology Company Synopsys Announces Acquisition of Ansys
Synopsys (NASDAQ:SNPS) has announced an acquisition of Ansys (NASDAQ:ANSS) that is expected to be completed 2025-H1. Under the…
Google Fiber Launches 20Gbps Internet Service: Now Download Heavy Games Like Marvel’s Spider-Man 2 In Seconds
Google Fiber has launched 20Gbps internet service, marking a significant upgrade from its 5Gbps and 8Gbps offerings.